

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 2633)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

FINANCIAL HIGHLIGHTS

- The revenue for the six months ended 30 September 2025 amounted to approximately HK\$766.6 million, representing a decrease of about 5.4% as compared to that of approximately HK\$810.0 million for the corresponding period of 2024.
- Profit from operations for the same period amounted to approximately HK\$183.4 million, representing a decrease of about 6.3% as compared to the profit from operations for the corresponding period of 2024 of approximately HK\$195.8 million.
- Profit attributable to equity shareholders of the Company for the same period amounted to approximately HK\$142.0 million, representing an increase of about 1.2% as compared to the profit for the corresponding period of 2024 of approximately HK\$140.3 million.
- The Board declared the payment of an interim dividend for the six months ended 30 September 2025 of HK4.25 cents per Share (for the total amount of approximately HK\$85.0 million), representing an increase of about 21.4% as compared to that of HK3.50 cents per Share (for the total amount of approximately HK\$70.0 million) for the corresponding period of 2024.

The Board is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 30 September 2025, together with the comparative figures for the corresponding period of 2024 as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 September 2025 – unaudited

		Six months ended 30 September	
		2025	2024
	<i>Note</i>	HK\$'000	HK\$'000
Revenue	4	766,553	810,002
Cost of sales		<u>(428,750)</u>	<u>(458,531)</u>
Gross profit		337,803	351,471
Other net income	5	14,575	9,560
Selling and distribution expenses		(61,498)	(63,126)
Administrative and other operating expenses		<u>(107,494)</u>	<u>(102,129)</u>
Profit from operations		183,386	195,776
Finance costs	6(A)	(12,912)	(20,528)
Share of profits of associates		<u>3,061</u>	<u>129</u>
Profit before taxation	6	173,535	175,377
Income tax	7	<u>(31,500)</u>	<u>(35,087)</u>
Profit for the period		<u>142,035</u>	<u>140,290</u>

		Six months ended 30 September	
		2025	2024
		HK\$'000	HK\$'000
	Note		
Other comprehensive income for the period			
<i>Item that will not be reclassified subsequently to profit or loss, net of nil tax:</i>			
Revaluation of financial assets at fair value through other comprehensive income		(139,498)	(23,854)
<i>Item that may be reclassified subsequently to profit or loss, net of nil tax:</i>			
Exchange differences on translation of financial statements of operations outside Hong Kong		(16)	(604)
Other comprehensive income for the period		(139,514)	(24,458)
Total comprehensive income for the period		<u>2,521</u>	<u>115,832</u>
Profit attributable to:			
Equity shareholders of the Company		142,035	140,290
Non-controlling interests		—	—
Total profit for the period		<u>142,035</u>	<u>140,290</u>
Total comprehensive income attributable to:			
Equity shareholders of the Company		2,521	115,832
Non-controlling interests		—	—
Total comprehensive income for the period		<u>2,521</u>	<u>115,832</u>
		HK cents	HK cents
Earnings per Share:			
Basic and diluted	8	<u>7.12</u>	<u>7.07</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 September 2025 – unaudited

		As at 30 September 2025 <i>HK\$'000</i>	As at 31 March 2025 <i>HK\$'000</i>
	<i>Note</i>		
Non-current assets			
Investment properties		158,900	163,880
Property, plant and equipment		1,503,139	1,494,092
Intangible assets		427,406	421,135
Interests in associates		53,886	50,825
Other non-current assets		65,475	68,487
Other financial assets		341,296	398,558
Deferred tax assets		10,661	10,231
		<u>2,560,763</u>	<u>2,607,208</u>
Current assets			
Inventories		347,711	332,879
Trade and other receivables	10	217,815	194,440
Current tax recoverable		6,344	1,590
Cash and cash equivalents		395,062	509,045
		<u>966,932</u>	<u>1,037,954</u>
Current liabilities			
Trade and other payables and contract liabilities	11	205,825	258,730
Bank loans		391,900	237,200
Lease liabilities		29,760	24,010
Current tax payable		58,758	33,200
		<u>686,243</u>	<u>553,140</u>
Net current assets		<u>280,689</u>	<u>484,814</u>
Total assets less current liabilities		<u>2,841,452</u>	<u>3,092,022</u>

		As at 30 September 2025 HK\$'000	As at 31 March 2025 HK\$'000
	<i>Note</i>		
Non-current liabilities			
Bank loans		444,500	476,500
Lease liabilities		38,462	35,501
Deferred tax liabilities		99,877	102,582
		<u>582,839</u>	<u>614,583</u>
NET ASSETS		<u>2,258,613</u>	<u>2,477,439</u>
CAPITAL AND RESERVES			
Share capital	12	20,002	19,942
Reserves		<u>2,214,392</u>	<u>2,433,278</u>
Total equity attributable to equity shareholders of the Company		2,234,394	2,453,220
Non-controlling interests		<u>24,219</u>	<u>24,219</u>
TOTAL EQUITY		<u>2,258,613</u>	<u>2,477,439</u>

NOTES

1 CORPORATE INFORMATION

Jacobson Pharma Corporation Limited is an exempted company with limited liability incorporated in the Cayman Islands. The Company is an investment holding company. The Company and its subsidiaries are principally engaged in the development, production, marketing and sale of generic drugs. The Company's shares were listed on the Main Board on 21 September 2016.

2 BASIS OF PREPARATION

The interim financial results set out in this announcement do not constitute the Group's interim financial report for the six months ended 30 September 2025 but are extracted from that interim financial report.

The interim financial report has been prepared in accordance with the applicable disclosure provisions of the Listing Rules, including compliance with Hong Kong Accounting Standard ("HKAS") 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). It was authorised for issue on 18 November 2025.

The interim financial information has been prepared in accordance with the same accounting policies adopted in the consolidated financial statements for the year ended 31 March 2025, except for the accounting policy changes that are expected to be reflected in the consolidated financial statements for the year ending 31 March 2026. Details of any changes in accounting policies are set out in note 3.

3 CHANGES IN ACCOUNTING POLICIES

The Group has applied the amendments to HKAS 21, *The effects of changes in foreign exchange rates – Lack of exchangeability* issued by the HKICPA to the interim financial information for the current accounting period. The amendments do not have a material impact on the interim financial information as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4 REVENUE AND SEGMENT REPORTING

(A) Revenue

The principal activities of the Group are development, production, marketing and sale of generic drugs. All the revenue for the six months ended 30 September 2025 and 2024 was recognised in accordance with HKFRS 15, *Revenue from contracts with customers*.

Revenue represents the sales value of goods supplied to customers less returns and sales rebates and is after deduction of any trade discounts.

(B) Segment reporting

The Group has one reportable segment which is generic drugs. This segment develops, manufactures and/or distributes a host of off-patent medicines for various therapeutic use. Currently the activities in this regard are primarily carried out in Hong Kong. The Group's chief operating decision maker, which has been identified as the Board, reviews the consolidated results of the Group for the purposes of resource allocation and performance assessment. Therefore, no additional reportable segment information has been presented.

(i) Geographic information

The following table sets out information about the geographical location of the Group's revenue from external customers. The geographical location of customers is based on the location at which the goods are distributed to distributors or the ultimate customers by the Group or the consignees.

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
Revenue from external customers		
Hong Kong (place of domicile)	743,792	769,417
Chinese Mainland	8,833	26,382
Macau	13,840	14,203
Others	88	—
	766,553	810,002

The following table sets out information about the geographical location of the Group's investment properties, property, plant and equipment, intangible assets, other non-current assets and interests in associates ("**specified non-current assets**"). The geographical location of the specified non-current assets is based on the physical location of the assets, in the case of investment properties, property, plant and equipment and non-current prepayments for property, plant and equipment, the location of the operations to which they are allocated, in the case of intangible assets and other non-current prepayments, and the location of operations, in the case of interests in associates.

	As at 30 September 2025 HK\$'000	As at 31 March 2025 HK\$'000
Specified non-current assets		
Hong Kong (place of domicile)	2,113,594	2,104,803
Chinese Mainland	24,452	23,213
Macau	128	96
Taiwan	4,675	4,350
Cambodia	65,957	65,957
	2,208,806	2,198,419

(ii) **Information about major customers**

For the six months ended 30 September 2025, the Group's customer base includes one (six months ended 30 September 2024: one) customer with whom transactions have exceeded 10% of the Group's revenue. Revenue from sales of generic drugs products to this customer, including sales to entities which are known to the Group to be under common control amounted to approximately HK\$393,395,000 (six months ended 30 September 2024: HK\$371,125,000).

5 OTHER NET INCOME

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
Subcontracting income	5,588	5,764
Rental income	4,510	5,227
Interest income from bank deposits and investments	4,391	6,902
Net distribution and logistic service income	901	1,557
Gain/(loss) on changes in fair value of investments in key-management insurance	196	(1,489)
Dividend income from an investment	114	1,981
Fair value loss on investment properties	(4,980)	(13,080)
Net foreign exchange (loss)/gain	(162)	659
Net loss on disposals of property, plant and equipment	(92)	(2,447)
Gain on deemed disposal of an associate	–	741
Government subsidies	–	115
Others	4,109	3,630
	14,575	9,560

6 PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging:

(A) Finance costs

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
Interest on bank loans and other borrowings	11,134	19,538
Interest on lease liabilities	1,778	990
	12,912	20,528

(B) Other items

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
Amortisation of intangible assets	8,947	9,275
Depreciation		
– owned property, plant and equipment	51,243	43,351
– right-of-use assets	16,343	18,838
Write-down of inventories	1,948	16,891

7 INCOME TAX

Income tax in the consolidated statement of profit or loss and other comprehensive income represents:

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
Current tax	34,616	36,844
Deferred tax	(3,116)	(1,757)
	31,500	35,087

The provision for Hong Kong Profits Tax is calculated by applying the estimated annual effective tax rate of 16.5% (six months ended 30 September 2024: 16.5%) to the six months ended 30 September 2025. Taxation for overseas subsidiaries is similarly calculated using the estimated annual effective rates of taxation that are expected to be applicable in the relevant jurisdictions.

8 EARNINGS PER SHARE

(A) Basic earnings per Share

The calculation of basic earnings per Share is based on the profit attributable to equity shareholders of the Company of HK\$142,035,000 for the six months ended 30 September 2025 (six months ended 30 September 2024: HK\$140,290,000) and the weighted average ordinary shares in issue during the period, calculated as follows:

Weighted average number of ordinary shares:

	Six months ended 30 September	
	2025	2024
	'000	'000
Ordinary shares issued at the beginning of the period	1,994,221	1,980,221
Effect of ordinary shares held for the Share Award Scheme	1,795	3,727
Weighted average number of ordinary shares in issue during the period	1,996,016	1,983,948

(B) Diluted earnings per Share

Diluted earnings per Share for the six months ended 30 September 2025 and 2024 were the same as the basic earnings per Share as there were no potential dilutive ordinary share in existence during both periods.

9 DIVIDENDS

(A) Dividends payable to equity shareholders of the Company attributable to the relevant reporting period

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
Interim dividend declared after the relevant reporting period of HK4.25 cents per Share (six months ended 30 September 2024: HK3.50 cents per Share)	85,009	70,008

The interim dividend has not been recognised as a liability at the end of the relevant reporting period.

(B) Dividends payable to equity shareholders of the Company attributable to the previous financial year, approved and paid/payable during the relevant reporting period

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
Final dividend in respect of the previous financial year, approved and paid during the following period, of HK5.50 cents per Share (six months ended 30 September 2024: final dividend in respect of the previous financial year, approved and payable during the following period, of HK3.00 cents per Share)	110,012	60,007
Special dividend in respect of the previous financial year, approved and paid during the following reporting period, of HK6.00 cents per Share (six months ended 30 September 2024: nil)	120,013	–
Less: Dividend of ordinary shares held by Share Award Scheme	–	(435)
	230,025	59,572

10 TRADE AND OTHER RECEIVABLES

	As at 30 September 2025 <i>HK\$'000</i>	As at 31 March 2025 <i>HK\$'000</i>
Trade receivables	164,459	145,091
Other receivables	9,295	9,762
Deposits and prepayments	42,453	39,449
Amounts due from an associate	1,608	138
	<u>217,815</u>	<u>194,440</u>

Ageing Analysis

As at the end of the Reporting Period, the ageing analysis of trade receivables (which are included in trade and other receivables) based on the invoice date and net of loss allowance, is as follows:

	As at 30 September 2025 <i>HK\$'000</i>	As at 31 March 2025 <i>HK\$'000</i>
Less than 1 month	122,413	103,100
1 to 6 months	41,630	41,604
Over 6 months	416	387
	<u>164,459</u>	<u>145,091</u>

11 TRADE AND OTHER PAYABLES AND CONTRACT LIABILITIES

	As at 30 September 2025 <i>HK\$'000</i>	As at 31 March 2025 <i>HK\$'000</i>
Trade payables	43,318	41,658
Salary and bonus payables	89,415	57,575
Payables and accruals for additions of property, plant and equipment	285	495
Other payables and accruals	48,373	134,835
Contract liabilities	24,434	24,167
	<u>205,825</u>	<u>258,730</u>

Ageing Analysis

As at the end of the Reporting Period, the ageing analysis of trade payables (which are included in trade and other payables and contract liabilities), based on the invoice date, is as follows:

	As at 30 September 2025 HK\$'000	As at 31 March 2025 HK\$'000
Less than 1 month	17,691	18,450
1 to 6 months	25,139	23,158
Over 6 months	488	50
	<u>43,318</u>	<u>41,658</u>

12 SHARE CAPITAL

	Number of Shares '000	Amount HK\$'000
Authorised:		
Ordinary shares of HK\$0.01 each at 31 March 2025, 1 April 2025 and 30 September 2025	<u>5,000,000</u>	<u>50,000</u>
Issued:		
At 31 March 2025 and 1 April 2025	1,994,221	19,942
Ordinary shares acquired for Share Award Scheme (<i>Note</i>)	(500)	(5)
Ordinary shares vested for the Share Award Scheme (<i>Note</i>)	<u>6,500</u>	<u>65</u>
At 30 September 2025	<u>2,000,221</u>	<u>20,002</u>

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All ordinary shares rank equally with regard to the Company's residual assets.

Note: On 16 October 2018, the Share Award Scheme was adopted by the Company. Pursuant to the Share Award Scheme, the Directors are authorised, at their discretion to determine individuals, including directors and employees of any companies in the Group, for granting them the Company's shares. The Share Award Scheme will be valid and effective for a period of 10 years commencing from 16 October 2018.

The Company's shares to be granted under the Share Award Scheme will be purchased and held by a trustee. The maximum of purchases by the trustee in any financial year will be fixed by the Board but such purchases will not result in the trustee holding at any time more than 3% of the total issued shares of the Company.

In addition, unless approved by the Board, no awarded Shares will be granted to any individual if the granting of such share award would result in the total number of shares granted to the individual during any 12-month period exceeding 0.5% of the total issued shares of the Company (0.1% of the total issued shares of the Company in case for an independent non-executive Director).

During the six months ended 30 September 2025, the trustee of the Share Award Scheme acquired 500,000 Shares through purchases on the open market. The total amount paid to acquire the Shares during the Reporting Period was approximately HK\$552,000. During the six months ended 30 September 2024, the trustee of the Share Award Scheme did not acquire any Shares through purchases on the open market.

During the six months ended 30 September 2025, the Company has granted a total of 6,500,000 Shares to eligible grantees, including certain Directors and employees of the Group. During the six months ended 30 September 2024, the Company has granted a total of 5,500,000 Shares to eligible grantees, including certain Directors and employees of the Group.

Details of the Shares awarded under the Share Award Scheme during the six months ended 30 September 2025 are as follows:

Date of grant	Number of Shares					Vesting date
	As at 1 April 2025	Granted during the period	Vested during the period	Lapsed/ cancelled during the period	As at 30 September 2025	
14 June 2025	–	6,500,000	(6,500,000)	–	–	29 July 2025

Details of the Shares awarded under the Share Award Scheme during the six months ended 30 September 2024 are as follows:

Date of grant	Number of Shares					Vesting date
	As at 1 April 2024	Granted during the period	Vested during the period	Lapsed/ cancelled during the period	As at 30 September 2024	
15 April 2024	–	5,500,000	(5,500,000)	–	–	30 May 2024

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

During the Reporting Period, the Group recorded a moderate decline in revenue compared with FY2025 Interim, primarily attributable to the early conclusion of the flu season. As a result, hospital admissions and clinic visits declined, which softened demand for associated healthcare services and medications.

In contrast, demand for chronic disease medicines remained resilient. This was driven by several key factors, including an ageing population, the rising prevalence of chronic diseases, and growing public health awareness, all of which continued to support steady growth in demand for essential medicines. The implementation of recent healthcare policies, particularly the Chronic Disease Co-Care (CDCC) Pilot Scheme, further contributed to the demand for cost effective generic drugs.

Against this backdrop, the Group strategically capitalised on emerging market opportunities. Solid progress was made through advancement in our research and development pipeline, enhancement in manufacturing capabilities, and refinement of our commercial strategies. These collective efforts enabled the Group to maintain stable operational performance and strengthen its competitive positioning throughout the Reporting Period.

Corporate responsibility remains an integral part of to the Group's business philosophy and practice. It fosters stakeholder trust, mitigates risks, promotes employee engagement, and reinforces the Group's reputation as a trusted healthcare partner in Hong Kong. Building on this foundation, the Group advanced its commitment to sustainable development under the "5 to Thrive" framework, which focuses on five key pillars: Corporate Governance, Product Responsibility, Societal Engagement, Environmental Stewardship, and Employee Commitment.

During the Reporting Period, environmental sustainability remained a strategic priority. The Group continued to pursue its established targets to reduce greenhouse gas emissions, waste generation, energy consumption, and water usage. In parallel, the Group continued to support charitable initiatives and university scholarship programmes, contributing to community well-being and talent development. These ongoing efforts in corporate governance and social responsibility had been recognised through accolades such as the Good Mandatory Provident Fund Employer Award and the Partner Employer Award.

RESULTS

The Group's total revenue for the Reporting Period amounted to HK\$766.6 million, representing a 5.4% decrease compared with FY2025 Interim. The decline was primarily due to the early conclusion of the flu season, which led to a lower demand for cold and flu medications.

Albeit the softened revenue, profit attributable to equity shareholders of the Company increased by 1.2% to HK\$142.0 million, primarily attributed to the Group's effective cost containment initiatives alongside process optimisation efforts to enhance operational efficiency.

OPERATIONAL PERFORMANCE

Solid Momentum in Key Therapeutic Categories

Albeit the early conclusion of the flu season which resulted in softened demand for cold and flu medications during the Reporting Period, there are other macro factors which contributed to sustained demand for a healthcare coverage.

Hong Kong's ageing population, together with the high prevalence of chronic conditions such as diabetes and hypertension, maintained a strong demand for long-term medications and regular medical consultations. Public health initiatives promoting preventive care and early treatment further heightened health awareness among the general population. In addition, the rising incidence of mental health conditions – including depression and anxiety associated with social isolation, chronic diseases, and economic stress – contributed to a notable increase in the use of psychotropic medications.

In line with these evolving healthcare trends, the Group's product portfolio delivered solid growth across key therapeutic categories. Cardiovascular products, particularly angiotensin II antagonists, recorded notable expansion, driven by increased usage of Losartan. Demand for hypnotics also strengthened, while cytotoxic lines grew on the back of higher consumption of Arsenic Trioxide Solution. Cancer hormone therapies recorded steady growth, supported by the new tender award for Exemestane Tablets during the Reporting Period.

Demand remained resilient across major chronic disease treatments in the Private Sector. Sales of cardiovascular and lipid-lowering medications – including angiotensin-converting enzyme inhibitors (ACEIs) such as Perindopril and Lisinopril, angiotensin II antagonists such as Losartan and Valsartan, and statins such as Atorvastatin and Rosuvastatin – continued to increase, reflecting demographic trends and the rising prevalence of chronic diseases.

R&D Pipeline on Track

The Group continued to make steady progress with its R&D pipeline during the Reporting Period. As of 30 September 2025, a total of 16 products had completed development and were submitted to the Department of Health of Hong Kong for registration approval. In addition, formulation studies had been completed for four products with commencement of stability testing during the Reporting Period, while 10 new items were added to the pipeline, further enriching the Group's portfolio across key therapeutic categories.

As of 30 September 2025, the Group's R&D pipeline comprised of 225 products in total. Of these, 68 had been approved for registration, 16 had been submitted for approval, 62 had completed development and were undergoing stability preparation or testing, and 26 were at the formulation or pre-formulation research stage.

During the Reporting Period, a total of 11 new products have been granted registration approval, paving the way for future market launches.

Advancing Manufacturing Capability and Capacity

The Group continued to strengthen its manufacturing capabilities and capacity through optimisation of its production processes and further improvements in operational efficiency.

Sterile manufacturing operations recorded strong growth, with eye drop output rising by 14.2% year-on-year to approximately 23.9 thousand litres, reinforcing the Group's leadership in aseptic production. Solid dosage output remained robust at 1.5 billion capsules and tablets, while the full integration of a manufacturing subsidiary contributed an additional 23 million solid dose units. Overall production of semi-solid and liquid dosage forms reached approximately 158.6 tonnes and 918.4 thousand litres, respectively.

These developments were supported by ongoing investment in automation and process innovation, with the aim of enhancing productivity while maintaining stringent quality standards.

The Group remains firmly committed to advancing its strategic priorities in specialty medicines and smart manufacturing. A new state-of-the-art production facility under development in Tai Po InnoPark – supported by the Hong Kong Government's New Industrialisation Acceleration Scheme (NIAS) – will serve as a cornerstone of this strategy. Equipped with artificial intelligence (AI)- and robotics-enabled production lines for sterile, solid, and oral liquid dosage forms, it is expected that the first trial production will commence by the first quarter of 2027, with full-scale operations expected by the first half of 2029.

This new manufacturing plant is being developed around three key pillars: ESG, safety, and user-centered design. Its blueprint incorporates energy-efficient systems, waste reduction measures, and responsible water management, supported by advanced environmental monitoring systems to help ensure sustainable operations. Layouts are optimised for safe flows of people and materials and feature ergonomic workspaces to minimise manual handling risks and enhance training and audit readiness. Automation, data analytics and robotics are specified across core processes to improve yield, support batch-to-batch consistency, and shorten time-to-release, while providing transparent data trails for continuous improvement.

BUSINESS DEVELOPMENT

In-license of Specialised Products

To further enhance its specialty drugs portfolio, the Group continued to leverage strategic in-licensing partnerships with global manufacturers, reinforcing its position in key therapeutic classes.

During the Reporting Period, the Group entered into exclusive agreements for 23 specialty drugs spanning infectious disease, neurology, gastroenterology, cardiology, endocrinology, anaesthesia and pain medicine, oncology and haematology, and vaccinology.

In infectious diseases, the portfolio has been expanded to include an oral solution for systemic mycoses and tablets for herpes zoster and genital herpes. In antiemetic care, both ampoule and tablet formulations are added to support nausea and vomiting management in chemotherapy patients.

The cardiovascular drugs portfolio was broadened with tablets and combination therapies for hypertension, blood pressure control, and heart failure, while acute pain management was supplemented through injectable formulations. In oncology and haematology, capsules targeting chronic myeloid leukaemia via tyrosine kinase inhibition were incorporated. Preventive care was further supported with quadrivalent influenza vaccines in injection and pre-filled syringe formats, alongside an injection for supportive therapy in specialised indications.

These in-licensing initiatives were selected based on their clinical profiles, market potential, and their relevance to identified medical needs. By enriching our specialty drugs portfolio across these critical therapeutic classes, the management has positioned the Group for sustainable growth while maintaining its commitment to improving patient care. The commercial potential of these products is expected to align with the Group's longer-term strategic objectives.

Strategic Partnership and Collaboration

Arsenol: Advancing a Transformative Therapy for Acute Promyelocytic Leukemia (“APL”)

Arsenol, an oral Arsenic Trioxide (ATO) formulation co-developed by The University of Hong Kong and the Group, successfully completed its pharmacokinetic study in Hong Kong in June 2025.

Positioned as a transformative treatment for APL, Arsenol has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (“**U.S. FDA**”). Following a successful pre-Investigational New Drug (“**IND**”) meeting and subsequent submission, the U.S. FDA granted IND clearance in January 2025. Efforts are being made to contemplate a phase III trial in the U.S. and a seeding trial in Chinese Mainland pending approvals from the relevant authorities.

Offering a safer and more convenient oral alternative to intravenous therapy for APL, Arsenol presents a good market potential supported by its efficacy and safety profile, with suitability for outpatient administration – factors that collectively contribute to reduce treatment-related healthcare costs and support patient compliance.

Meanwhile, adoption continues to expand in Malaysia, Singapore, and Taiwan, with regulatory activities progressing in selected territories.

Advancing Cancer Care with Axicabtagene Ciloleucel (“Yikaida”)’s Launch in Macau

The Group achieved another milestone with the first administration of Yikaida, a Chimeric Antigen Receptor T-cell (“CAR-T”) therapy, in Macau – representing the therapy’s debut in the market.

This followed the earlier launch of supply chain and patient care support for the therapy in Hong Kong through a strategic collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) and Shanghai Fosun Kairos Biotechnology Co., Ltd.* (復星凱瑞(上海)生物科技有限公司).

Leveraging the Group’s licensed Advanced Therapeutic Product (“ATP”) logistics platform, Yikaida was introduced as a next-generation treatment option for diffuse large B-cell lymphoma (“DLBCL”). Supported by published clinical evidence, the therapy has received regulatory approvals in major markets including the United States, the European Union, and Japan. It remains the only CAR-T therapy approved as a second-line treatment for DLBCL by both the U.S. FDA and the National Medical Products Administration in China. The pivotal ZUMA-7 study reported improved survival outcomes over standard therapy.

Operationally, Yikaida streamlines the treatment process by eliminating the need for international shipment of patient samples, thereby reducing turnaround time and logistics costs. With its ATP licence, the Group’s logistics division is one of only two authorised CAR-T handlers in Hong Kong, further strengthening its leadership in the advanced therapeutics segment.

e-Jacob Pharma2U: Enhancing Digital Procurement for Healthcare Professionals

The Group made solid progress in advancing e-Jacob Pharma2U, its proprietary e-ordering platform for healthcare professionals. Designed to streamline digital procurement for private clinics, the platform has become a key channel through which users can access pharmaceutical products and medical supplies via both mobile and web interfaces.

During the Reporting Period, e-Jacob Pharma2U recorded steady growth in user engagement and transaction volume, reflecting rising trust and adoption among private practitioners. As of 30 September 2025, over 1,000 clinics – including general practitioners, medical specialists, dentists, and veterinarians – have registered on the platform, with a majority actively using it for their procurement needs.

Several enhancements were introduced to improve functionality and user experience. New features such as delivery label requests and optimised offers selection mechanisms were added to enhance convenience and service efficiency. Targeted promotional campaigns were implemented to help sustain customer engagement and loyalty. The platform’s product portfolio was also expanded to include new launches, such as Medtronic’s Simplera, further broadening its appeal to healthcare practitioners.

* For identification purpose only

Looking ahead, the Group will continue to develop e-Jacob Pharma2U by enhancing user experience, expanding product offerings, and exploring strategic collaborations to support sustainable growth. Future optimisation will focus on improving interface design, order management, and data analytics to provide a more seamless and efficient procurement experience, while new high-quality pharmaceutical and medical supply lines will address the evolving needs of private clinics and specialist practitioners.

OUTLOOK

Hong Kong's economy recorded moderate growth in the first half of 2025, with real GDP rising 3.1% year-on-year, up from 2.7% in the same period of 2024. The government maintains its full-year GDP forecast at 2–3%, supported by fiscal and policy measures, although risks remain from escalating trade tensions and a slowdown in the Chinese Mainland.

Amid these conditions, Hong Kong's pharmaceutical market is expected to maintain steady growth, driven by an ageing population, the rising prevalence of chronic diseases, and continued demand for cost-effective treatments. Generics are gaining traction across both public and private healthcare sectors, with private clinics and hospitals playing a key role in adoption. This trend is further reinforced by rising healthcare expenditure and strategic opportunities linked to access to Chinese Mainland's generics market via the Guangdong-Hong Kong-Macau Greater Bay Area ("**GBA**").

Government policies and regulatory initiatives, including accelerated approval processes, the Hospital Authority's Drug Formulary, and R&D subsidies, are enhancing competitiveness and facilitating market entry. Integration with the GBA, including multi-center clinical trials and harmonised regulations, reduces costs and streamlines development, while creating opportunities for both domestic growth and regional exports.

Complementing this, Hong Kong's biotechnology and clinical trial ecosystem – supported by talent attraction schemes, cross-border innovation zones, and partnerships with global pharmaceutical companies – is continuing to develop. This is expected to support innovation, improve clinical trial efficiency, and broaden access to regional and international markets. Together, these factors provide a platform from which local pharmaceutical firms may pursue sustainable growth, expand their presence in Asia's life sciences landscape, and contribute to Hong Kong's role as a regional hub for both generic and innovative therapeutics.

To capitalise on these developments, the Group will continue to reinforce its market position and executing its growth strategies in Hong Kong and selected Asian market. Through targeted in-licensing and R&D in chronic and specialty therapies, together with strengthened commercial, regulatory, and regional partnerships, the Group aims to deliver cost-effective solutions to a wider patient base.

By leveraging supportive policy reforms and demographic trends, the Group is well-placed to pursue sustainable growth, contribute to improved health outcomes, and support the development of a more efficient, patient-centred healthcare system.


REMUNERATION POLICY

As of 30 September 2025, the Group has a total of 1,792 employees (compared to 1,730 employees as of 30 September 2024). For this Reporting Period, the total staff cost of the Group was HK\$259.9 million, compared to HK\$243.4 million for the six months ended 30 September 2024 with the corresponding enhancement in staff deployment supporting the growth and development of the Group. All of the Group's employees have entered into standard employment contracts with the Group. Remuneration packages for the Group's employees in general comprise one or more of the following elements: basic salary, sales-related incentives, productivity-related incentives and work performance bonuses. The Group sets out performance attributes for its employees based on their positions and job functions. It periodically reviews their work performance against the Group's strategic objectives and targets. The results of such reviews are taken into consideration when assessing salary adjustments, bonus awards, promotions, staff development plans and training needs. The Group provides various benefit schemes to its employees including annual leave entitlement, mandatory provident fund, group medical insurance and life insurance. A workers union has been established for the Group's employees in China according to local labour laws. As of 30 September 2025, the Group has not experienced any strikes or any labour disputes with its employees which would likely have had a material impact on its business.

The Group places a high value on recruiting, developing and retaining its employees. It maintains high recruitment standards and provides competitive compensation and benefit packages to attract and retain talents. The Group also emphasises on training and developing employees. In addition to different skill and knowledge based in-house training programs, the Group has training sponsorship policy to encourage its employees to attend external training to enhance their job competencies.

FINANCIAL REVIEW


Revenue



The Group recorded a moderate decline in revenue to HK\$766.6 million during the Reporting Period, representing a decrease of HK\$43.4 million, or 5.4%, compared with FY2025 Interim. The decline was primarily due to reduced demand for flu-related treatments and medications following the early conclusion of the flu season.

Albeit this, overall healthcare demand in Hong Kong remained resilient, supported by an ageing population, increasing prevalence of chronic conditions, and rising public health awareness. These structural trends continued to underpin steady demand for medications and medical consultations. In addition, mental health needs expanded amid ongoing social and financial pressures, with higher incidences of depression and anxiety linked to social isolation, chronic diseases, and economic stress – driving increased demand for psychotropic medicines. The Chronic Disease Co-Care (CDCC) Pilot Scheme, together with other supportive healthcare policies, is expected to further stimulate sustained growth in the demand for affordable and effective generic medicines in Hong Kong.


Revenue by geographic locations



During the Reporting Period, Hong Kong remained the primary revenue driver, accounting for 97% of the total revenue, and recorded a moderate revenue decline of HK\$25.6 million or 3.3% compared to FY2025 Interim. This decrease was primarily attributed to the early conclusion of the flu season and the improving uptake of seasonal influenza vaccination, which resulted in reduced demand for cold and flu medications. Nonetheless, demand for healthcare services and medications attributable to an aging population, rising incidence of chronic diseases, public health consciousness, and growing need for mental health remained resilient in the market.

In Chinese Mainland, the revenue decreased by HK\$17.6 million or 66.7%, primarily due to reduced demand for the Group's cold and flu and gastrointestinal product ranges during the Reporting Period. In Macau, revenue remained relatively stable during the Reporting Period.

Cost of Sales




The decrease in cost of sales of HK\$29.7 million or 6.5% was generally in line with the decline in overall sales of the Group during the Reporting Period. Material cost continued to be the major component, contributing approximately 40% of the total cost of sales, while staff cost and other production cost contributed 38% and 22%, respectively.

The decrease in material cost of HK\$30.7 million or 15.3% was attributable to the lower production resulting from the softened demand for cold and flu products, which was caused by the early conclusion of the flu season, and change in sales mix during the Reporting Period.

The increase in staff cost of HK\$5.9 million or 3.8% is reflected in the salary increment and additional headcount to manage and support the operations in our newly revamped pharmaceutical facilities in Hong Kong during the Reporting Period. The other production costs decreased by HK\$4.9 million or 4.9% was generally in line with the decline in overall sales of the Group during the Reporting Period.

Profit from Operations



The decrease in profit from operations by HK\$12.4 million or 6.3% to HK\$183.4 million was mainly attributable to the decrease in gross profit of HK\$13.7 million resulting from the revenue decline during the Reporting Period.


Finance Costs

The decrease in finance costs by HK\$7.6 million or 37.1% was mainly attributable to the decreasing interest rates in the market during the Reporting Period.

Income Tax

The decrease in income tax primarily reflected the lower assessable profits during the Reporting Period compared to FY2025 Interim.

Profit Attributable to Equity Shareholders



The profit attributable to equity shareholders increased by HK\$1.7 million or 1.2% to HK\$142.0 million mainly attributable to the decrease in finance costs of HK\$7.6 million, the heightened share of profits of associates of HK\$2.9 million and the reduced income tax of HK\$3.6 million, which were offset partially by the decrease in profit from operations of HK\$12.4 million resulting from the revenue decline during the Reporting Period.

Assets

Investment properties and property, plant and equipment

The increase in property, plant and equipment and investment properties primarily reflected the additions of HK\$76.6 million mainly arose from the acquisitions of properties, plant and machinery used by our pharmaceutical manufacturing plants, which was offset partially by the depreciation of HK\$67.6 million and the fair value loss on investment properties of HK\$5.0 million.

Intangible assets

The increase in intangible assets was primarily attributable to the capitalised development costs of drugs and software system of HK\$15.2 million, which were offset partially by the amortisation of HK\$8.9 million.

Inventories

The increase in inventories by HK\$14.8 million or 4.5% was primarily attributable to the additional safety inventories maintained in our newly revamped pharmaceutical facility in Hong Kong and the expanded range of products mix resulted from the successful launch of new products to the markets.

Cash and cash equivalents

As at 30 September 2025, approximately 99.1% of cash and cash equivalents were denominated in Hong Kong dollars (as at 31 March 2025: 99.3%), while the remaining balances were denominated in Renminbi, Macau pataca, Taiwan dollars, and United States dollars.

Liabilities

Bank loans

The increase in bank loans by HK\$122.7 million or 17.2% as at 30 September 2025 was mainly attributable to the additions of bank loans principally utilised to finance capital expenditure on a newly revamped pharmaceutical facilities in Fotan and a new state-of-the-art production facility under development in Tai Po InnoPark during the Reporting Period. As at 30 September 2025, all bank loans of the Group were denominated in Hong Kong dollars.

LIQUIDITY, CAPITAL RESOURCES AND CAPITAL STRUCTURE

The Group consistently adheres to conservative fund management. The solid capital structure and financial strength continue to provide a solid foundation for the Group's future development as well as mergers and acquisitions. The Group's primary uses of cash are to fund working capital, capital expenditures and mergers and acquisitions. During the Reporting Period, the Group funded its cash requirements principally from cash generated from operations and bank borrowings.

CHARGE ON GROUP ASSETS

As at 30 September 2025, the Group had no assets pledged against bank loans.

NET GEARING RATIO

The net gearing ratio of the Group (bank loans less cash and cash equivalents, divided by total equity multiplied by 100%) increased from 8.3% as at 31 March 2025 to 19.5% as at 30 September 2025, mainly attributable to the increase in bank loans of HK\$122.7 million during the Reporting Period.

FINANCIAL RISK ANALYSIS

Management considered that the Group did not have significant exposure to fluctuation in exchange rates and any related hedges.

CONTINGENT LIABILITIES

As at 30 September 2025, the Group did not have any significant contingent liabilities.

SIGNIFICANT INVESTMENT HELD, MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group had no material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period. The Group had no individually significant investments held during the Reporting Period.

NON-ADJUSTING EVENTS AFTER THE REPORTING PERIOD

No significant event has taken place subsequent to 30 September 2025 and up to the date of this interim results announcement.

FUTURE PLANS FOR MATERIAL INVESTMENT OR CAPITAL ASSETS

As at the date of this interim results announcement, there were no material investments or additions of capital assets authorised by the Board.

PRINCIPAL RISKS AND UNCERTAINTIES

The following is a summary of the principal risks and uncertainties identified by the Company which may have material and adverse impact on its business or operation, and how the Company endeavours to manage the risks involved. There may be other principal risks and uncertainties in addition to those shown below which are not known to the Company or which may not be material now but could turn out to be material in the future.

- The Group operates in pharmaceutical manufacturing industry and is subject to various regulations; failure to comply with pharmaceutical or other regulations may restrict our business operations. The Group has dedicated quality control and quality assurance team in each manufacturing plant to ensure compliance with relevant regulations.
- The Group made a number of successful acquisitions; however, the Group may not be able to successfully identify, consummate and integrate future mergers or acquisitions. The Group will continue to seek for new acquisition opportunities and perform adequate due diligence to assess the potential acquisition targets.
- The Group operates in generic drugs business and development of new products provides additional growth driver for the Group. However, we may not be able to develop and launch new product according to our schedule. The Group continues to invest in the R&D of new products and engage external experts to enhance our overall R&D capability.
- The Group is also exposed to risks of liability and loss due to defective products as well as damage to the Group's reputation. While the Group has taken out product liability insurance, the insured amount may not be sufficient to cover all damages claimed. The Group has a designated production and quality assurance team to monitor product quality in each manufacturing plant to ensure they are in compliance with respective specifications.

The Company believes that risk management is essential to the Group's efficient and effective operation. The Company's management assists the Board in evaluating material risk exposure in the Group's business, participating in formulating appropriate risk management and internal control measures, and ensuring its implementation in the daily operational management.

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Group is primarily engaged in the development, production, marketing and sale of generic drugs, a line of business that does not have any material impact on the environment. The key environmental impact from the Group's operation is related to electricity, water and paper consumption. The Group is fully aware of the importance of sustainable environmental development, and has implemented a number of measures to encourage environmental protection and energy conservation.

During the Reporting Period, there was no significant regulatory non-compliance with applicable environmental laws and regulations.

COMPLIANCE WITH LAWS AND REGULATIONS

During the Reporting Period, the Group was in compliance with the applicable laws and regulations which have significant impacts on the Group in all material respects.

CORPORATE GOVERNANCE HIGHLIGHTS

The Group is committed to maintaining high corporate governance standards to safeguard the interests of shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as its own code of corporate governance.

During the Reporting Period, the Company has complied with all the code provisions of the CG Code and adopted most of the best practices set out therein, except for the following provision:

Code provision C.2.1 of the CG Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing.

Currently, Mr. Sum is the chairman of the Board and chief executive officer of the Company and accordingly, there is no written terms setting out the division of responsibilities between the chairman and chief executive. The Board considers that Mr. Sum is the founder of the Group and had been managing the Group's business and overall strategic planning since its establishment, the vesting of the roles of chairman of the Board and chief executive officer of the Company in Mr. Sum is beneficial to the business prospects and management of the Group by ensuring consistent leadership within the Group and enabling more effective and efficient overall strategic planning for the Group. The Board also considers that the balance of power and authority of the Board for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively.

The Board will continue to review and consider splitting the roles of chairman of the Board and chief executive officer of the Company at an appropriate time, taking into account the circumstances of the Group as a whole.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding securities transactions of the Directors. Having made specific enquiry with the Directors, all Directors confirmed that they have complied with the required standard as set out in the Model Code throughout the Reporting Period.

AUDIT COMMITTEE

The Board has established an audit committee (the “**Audit Committee**”) which currently comprises three independent non-executive Directors, namely Mr. Young Chun Man, Kenneth (Chairman), Dr. Lam Kwing Tong, Alan and Mr. Luk Ting Lung, Alan. The primary duties of the Audit Committee include reviewing and supervising the Group’s financial reporting process, internal control and risk management systems, preparing financial statements and internal control procedures. It also acts as an important link between the Board and the external auditor in matters within the scope of the group audit.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor its subsidiaries has purchased, sold or redeemed any of the Company’s listed securities (including sale of treasury shares) throughout the Reporting Period. As at 30 September 2025, the Company did not hold any treasury shares.

REVIEW OF INTERIM RESULTS

The interim results for the six months ended 30 September 2025 are unaudited, but have been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the HKICPA, whose unmodified review report is included in the 2025/2026 Interim Report to be sent to shareholders of the Company.

The Audit Committee, together with management of the Company, has also reviewed the interim results for the six months ended 30 September 2025.

INTERIM DIVIDEND

The Board declared the payment of an interim dividend per Share for the six months ended 30 September 2025 of HK4.25 cents for the total amount of approximately HK\$85.0 million (six months ended 30 September 2024: HK3.50 cents). The interim dividend will be paid on 18 December 2025 (Thursday) to shareholders whose names appear on the register of members of the Company on 4 December 2025 (Thursday), the record date. The details of interim dividend of the Group are set out in note 9 to this interim results announcement.

CLOSURE OF REGISTER OF MEMBERS

In order to determine the entitlement of shareholders of the Company to receive the interim dividend, the register of members of the Company will be closed from 3 December 2025 (Wednesday) to 4 December 2025 (Thursday), both days inclusive, during which period no transfer of Shares will be registered. The record date will be 4 December 2025 (Thursday). All transfer documents, accompanied by the relevant share certificates, shall be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on 2 December 2025 (Tuesday).

PUBLICATION OF THIS INTERIM RESULTS ANNOUNCEMENT AND THE 2025/2026 INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and of the Company (www.jacobsonpharma.com). The 2025/2026 Interim Report containing all the information required by the Listing Rules will be published on the respective websites of the Stock Exchange and the Company and will be dispatched (if requested) to the shareholders of the Company in due course.

By Order of the Board
Jacobson Pharma Corporation Limited
YIM Chun Leung
Executive Director

Hong Kong, 18 November 2025

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Mr. Luk Ting Lung, Alan as independent non-executive Directors.

GLOSSARY

In this announcement, unless otherwise specified, the following glossary applies:

“2025/2026 Interim Report”	the interim report of the Company for the six months ended 30 September 2025
“Board”	the board of directors of the Company
“CG Code”	Corporate Governance Code as amended or supplemented from time to time contained in Appendix C1 to the Listing Rules
“China”, “Chinese Mainland” or “the PRC”	the People’s Republic of China excluding, for the purpose of this interim results announcement, Hong Kong, Macau and Taiwan
“Company”, “our Company” or “the Company”	Jacobson Pharma Corporation Limited, an exempted company incorporated in the Cayman Islands with limited liability on 16 February 2016
“Director(s)”	the director(s) of the Company
“ESG”	environmental, social and governance
“FY2025”	the year ended 31 March 2025
“FY2025 Interim”	the six months ended 30 September 2024
“FY2026”	the year ending 31 March 2026
“FY2026 Interim” or “Reporting Period”	the six months ended 30 September 2025
“GDP”	Gross Domestic Product
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Jacobson”, “Group”, “the Group”, “we” or “our”	the Company and its subsidiaries and, in respect of the period before we became the holding company of our present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Macau”	the Macau Special Administrative Region of the PRC
“Main Board”	Main Board of the Stock Exchange
“Model Code”	Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
“Mr. Sum”	Mr. Sum Kwong Yip, Derek, our chairman, executive Director, chief executive officer and one of our controlling shareholders
“Private Sector”	refers to non-Public Sector
“Public Sector”	refers to public sector institutions and clinics in Hong Kong
“R&D”	research and development
“Share(s)” or “share(s)”	ordinary share(s) in the capital of the Company with nominal value of HK\$0.01 each
“Share Award Scheme”	the share award scheme adopted by our Company on 16 October 2018 and amended on 21 September 2023
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“treasury shares”	has the meaning as described in the Listing Rules